Parenteral Manual

DAUNOrubicin

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
DAUNOMYCIN, CERUBIDINE
Classification: 
Antineoplastic, antibiotic (anthracycline) - CYTOTOXIC
Original Date: 
August 2005
Revised Date: 
June 2015
Indications: 
  • Acute lymphoblastic leukemias (ALL)
  • Acute non-lymphoblastic leukemias (ANLL)
  • Non-Hodgkin?s lymphoma (NHL)

THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.

Reconstitution and Stability: 
  • Reconstitute 20 mg powder vial with 4 mL sterile water
  • Reconstituted 5 mg/mL solution is a clear deep red color, stable for 7 days in refrigerator
  • Stable in D5W, 0.9% NaCl or combinations for 7 days at room temperature or in the refrigerator
  • Stable in syringe for 24 hours at room temp, 7 days refrigerated
  • Color change to blue/purple indicates decomposition - discard solution
  • Protect from light
Compatibility: 

- Solutions Compatible: D5W, 0.9% NaCl, dextrose-saline combinations

- Additives/Above Cassette Compatible: no information

- Y-site Compatible: cytarabine, filgrastim, hydrocortisone sodium succinate, methotrexate, ondansetron, KCl, sodium bicarbonate

- Incompatible: allopurinol, dexamethasone, heparin, piperacillin

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Direct

YES
Usual dilution: 100 mg/mL
Infusion rate: do not exceed 500 mg/minute in adults

IV Intermittent Infusion YES, central line preferred
Doses up to 30 mg/m2 over 15 minutes into the tubing of a freely running IV
IV Continuous Infusion NO
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • 45 mg/m2  x 2 up to 100 mg/m2 Q 3 weeks
  • Use ideal body weight for dosage calculations (if patient is obese, or ascites is present)
  • Total cumulative lifetime dose should not usually exceed 450 mg/m2 or 350 mg/m2 with concomitant use of mediastinal or cardiac radiation, 300 mg/m2 in children > 2 years of age and < 12 years, and 10 mg/kg in children < 2 years of age

- Dosage may differ according to protocol

Dosage adjustment in renal/hepatic impairment:

  • Reduce dose in severe renal impairment
  • Reduce dose in hepatic impairment (see below)
Serum Bilirubin Dose

25-50 micromol/L

50% of usual dose

51-85 micromol/L

25% of usual dose

>85 micromol/L

Contraindicated

  • Children <0.5 m2 or <2 years of age should be dosed on a mg/kg basis (to obtain mg/kg from mg/m2, divide by 30, i.e: 1 m2 = 30 kg)
Potential hazards of parenteral administration: 

Immediate (within a few minutes to hours):

  • Transient arrhythmias, hypotension
  • Nausea, vomiting (moderately high emetogenic potential), anorexia, abdominal pain
  • Streaks along vein of injection (likely a flare reaction, not extravasation - may respond to antihistamines)
  • Facial flushing with rapid injection
  • VESICANT: will cause tissue necrosis if extravasated.  First sign is usually pain.  Refer to policy for administration of vesicant chemotherapy; refer to Treatment of Infiltrations, Section H, Infusion Therapy Manual. If extravasation occurs, click HERE for treatment guidelines. 

Delayed (within a few days to weeks):

  • Alopecia
  • Myelosuppression, nadir 10 - 14 days
  • Cardiotoxicity (related to cumulative life-time dose), congestive heart failure, cardiomyopathy
  • Oral mucositis, diarrhea
  • Red coloration of urine, 1 - 2 days post administration

 - Treatment for unusual side effects are available through the study chair identified on the front page

Notes: 
  • Monitor hematological status, liver function
  • ECG and echocardiogram recommended before treatment started and follow cardiac function regularly with subsequent doses; cumulative dose must be recorded, consult protocol for specific intervals
  • Contraindicated in patients with myocardial lesions
  • Use with caution in liver impairment
  • Use with caution in patients who have had thoracic radiation and do not use at the same time as radiation therapy

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.